Semaglutide vs Tirzepatide vs Retatrutide: The Three Generations of GLP-1 Therapy

TL;DR

• Semaglutide — single agonist. Activates GLP-1 only. FDA-approved. Longest track record.
• Tirzepatide — dual agonist. Adds GIP. FDA-approved. Larger weight-loss numbers than semaglutide.
• Retatrutide — triple agonist. Adds glucagon. Investigational. Largest weight-loss numbers yet seen in this class.
• The shorthand: each generation adds a receptor, each adds roughly 3–6% more weight loss in trials, each is a step less proven than the last.

If you only remember one thing: more receptors = more weight loss, but also less safety data and less availability. Each generation is more effective and more experimental than the last.

The headline difference, in one sentence

This is the only peptide family where the side-by-side story is linear: each new drug adds one receptor to the last, and each adds roughly 3–6% more body weight lost in trials.

What each generation adds

Generation 1 — Semaglutide: the GLP-1 agonist

The foundational drug in this class. GLP-1 agonism drives appetite suppression (acts on hypothalamic centers), slowed gastric emptying (fewer hunger spikes), and improved insulin response (glucose-dependent, so lower hypoglycemia risk than insulin).

Semaglutide has the longest approved use in this family — FDA-approved 2017 for diabetes, 2021 for obesity. The deepest post-market safety data lives here.

Generation 2 — Tirzepatide: add GIP

Tirzepatide is semaglutide's mechanism plus GIP (glucose-dependent insulinotropic polypeptide) receptor agonism. GIP alone isn't very useful in obesity, but combined with GLP-1 it enhances insulin secretion in glucose-dependent ways, improves adipose handling of nutrients, and may soften some GI side effects of GLP-1 agonism (debated).

Approved 2022 for diabetes, 2023 for obesity. Has multi-year human data but shorter track record than semaglutide.

Generation 3 — Retatrutide: add glucagon

Retatrutide adds glucagon receptor agonism to the dual mechanism. This sounds counterintuitive — glucagon normally raises blood sugar — but in this multi-receptor context it produces increased energy expenditure (the body burns more calories at rest), improved liver fat handling (relevant for NAFLD research), and a metabolic-rate component on top of GLP-1's appetite suppression.

Still in trials. Preliminary Phase 2 data showed ~24% weight loss at 48 weeks — the highest in this drug class. Not yet FDA-approved as of 2026.

Pick semaglutide if...

• You want the most-studied, longest-proven option in the family.
• You need pharmacy access and insurance coverage — semaglutide is the most broadly available.
• You want an oral option — Rybelsus is the only oral GLP-1 agonist in this family.
• Cost matters — semaglutide is typically the cheapest per cycle.
• Moderate weight-loss targets are sufficient for the research.

Pick tirzepatide if...

• You want a balance between efficacy and safety track record.
• The research target is larger weight-loss effect than semaglutide provides.
• You're studying diabetes glycemic control specifically — the GIP component strengthens A1c reduction.
• You're comfortable with slightly less long-tail safety data in exchange for the stronger effect.

Pick retatrutide if...

• You're studying maximum weight-loss effect in this drug class.
• You want to research glucagon receptor agonism specifically — it's currently the only commercially relevant triple agonist.
• You're researching energy expenditure mechanisms alongside appetite suppression.
• You accept the investigational status and the less-mature safety profile in exchange for the efficacy data.

Honest tradeoffs across the three

• GI side effects (nausea, vomiting, diarrhea) are present across all three, typically most pronounced during titration. Rates climb slightly with each generation — more receptors means more pathways producing nausea.
• Lean mass loss scales with total weight loss. Retatrutide's larger effect means larger absolute lean mass loss without protein and resistance-training countermeasures.
• Discontinuation regain: all three are associated with weight regain after stopping. None is a one-and-done intervention.
• Cardiovascular profile: GLP-1/GIP agonists have favorable cardiovascular outcomes data. Glucagon agonism's long-term cardiac profile is less mature. Semaglutide has the cleanest record here simply due to time.
• Compounding/availability: semaglutide compounding is most available; tirzepatide compounding has tightened; retatrutide compounding is the wild west right now — expect rapid regulatory changes.
• Dosing: all three are weekly subcutaneous injections. All require dose titration to minimize side effects.

Quick decision shortcut

Where each one fits on the risk/reward curve

• Semaglutide: lower ceiling, lowest risk, best data.
• Tirzepatide: higher ceiling, moderate risk, solid data.
• Retatrutide: highest ceiling, highest risk, preliminary data.

There's no universally correct answer. It depends on how much weight-loss effect you're after and how much uncertainty you're willing to tolerate about rare long-term effects that haven't had time to surface.

Where to read more

• Full breakdowns: Semaglutide, Tirzepatide, Retatrutide.
• Head-to-head pairings: Semaglutide vs Tirzepatide, Tirzepatide vs Retatrutide.
• The next axis: [GLP-1 vs Amylin Agonists](/wiki/glp-1-vs-amylin-agonists) — what happens when you add a completely different hormone class to the stack.

Important context

Semaglutide and tirzepatide are FDA-approved prescription medications. Retatrutide is investigational and not approved for any indication. Compounded versions of all three exist in research-supply channels with varying regulatory status by jurisdiction. All three have meaningful side-effect profiles and monitoring requirements. Nothing on this page is medical advice.